At a conference in Hyderabad this week, pharmaceutical companies highlighted the growing role of artificial intelligence in evolving the drug development process. Companies like Amgen and Parexel showcased how AI can reduce trial times, with Parexel demonstrating a model that speeds up drug safety reports by 30-45 minutes. Industry experts believe that AI can potentially halve the costs and time needed to develop drugs, cutting down the process from over a decade to just a few years.

Beyond speeding up trials, AI is also aiding in drug discovery and medical diagnostics. For instance, AI is being used to repurpose existing drugs for new uses and to analyse medical images, potentially identifying conditions such as cancer that might be missed by human doctors. Medtronic's CTO stressed that integrating AI across the industry is essential to its future success.

Despite these technological strides, the conference was overshadowed by ongoing uncertainty regarding US President Trump's proposed tariffs on pharmaceutical imports. Companies, particularly those based in India, expressed concern over the potential impact of these tariffs, with some, like Dr Reddy's, opting to take a 'wait and watch' approach until further clarity emerges. This tariff uncertainty remains a pressing issue for India's pharmaceutical industry, which is a major exporter of affordable drugs to the US.